Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Passos · SciRah

Researcher profile · Semantic Scholar

V. Passos

Share profile

V. Passos — researcher profile on SciRah

h-index: 17
Works: 47
Citations: 1,254

Most-cited papers

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
V. Subbiah, R. Kreitman, Z. Wainberg, A. Gazzah +19 more
2023Nature Medicine311 citations Open access
Semantic Scholar
ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
B. Cho, Dong-Wan Kim, A. Bearz, S. Laurie +15 more
2017Journal of Thoracic Oncology170 citations Open access
Semantic Scholar
Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
V. Passos, J. J. Souza, N. Musolino, M. Bronstein
2002Journal of Clinical Endocrinology and Metabolism111 citations Open access
Semantic Scholar
Systemic hypertension, diabetes mellitus, and dyslipidemia in relation to body mass index: evaluation of a Brazilian population.
C. Cercato, M. Mancini, Ana Maria Carvalho Arguello, V. Passos +2 more
2004Revista do Hospital das Clínicas93 citations Open access
Semantic Scholar
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
D. Tan, E. Felip, G. de Castro, B. Solomon +19 more
2023Journal of Clinical Oncology83 citations
Semantic Scholar
Genes Differentially Expressed in Prolactinomas Responsive and Resistant to Dopamine Agonists
V. Passos, M. A. Fortes, D. Giannella-Neto, M. Bronstein
2008Neuroendocrinology66 citations
Semantic Scholar
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
B. Cho, R. Obermannova, A. Bearz, M. McKeage +19 more
2019Journal of Thoracic Oncology65 citations Open access
Semantic Scholar
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.
P. Garrido, J. Pujol, Edward S. Kim, J. Lee +10 more
2021Future Oncology40 citations Open access
Semantic Scholar
Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.
M. Nishio, E. Felip, S. Orlov, Keunchil Park +12 more
2019Journal of Thoracic Oncology32 citations Open access
Semantic Scholar
A randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial.
P. Hoff, D. Saragiotto, C. Barrios, A. del Giglio +9 more
2012Journal of Clinical Oncology31 citations
Semantic Scholar
Safety and efficacy of pasireotide in dumping syndrome—results from a phase 2, multicentre study
Jan Tack, J. Aberle, J. Arts, M. Laville +10 more
2018Alimentary Pharmacology and Therapeutics29 citations
Semantic Scholar
Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
E. Felip, S. Orlov, Kyung-Ah Park, C.-J. Yu +12 more
201629 citations Open access
Semantic Scholar
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
P. Hoff, D. Saragiotto, C. Barrios, A. del Giglio +9 more
2014Journal of Clinical Oncology24 citations
Semantic Scholar
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
C. Cristina, G. Díaz-Torga, R. Goya, S. Kakar +5 more
2007Molecular Cancer24 citations Open access
Semantic Scholar
Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Ying Hong, V. Passos, Pai‐Hsi Huang, Yvonne Y. Lau
2017Journal of clinical pharmacology23 citations
Semantic Scholar
Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil.
J. Valentim, V. Passos, F. Mataveli, A. Calabró
2008Arquivos brasileiros de endocrinologia e metabologia20 citations Open access
Semantic Scholar
Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
Yi-Long Wu, Yuan-Kai Shi, D. Tan, Xiao-Qing Liu +10 more
2020Lung Cancer17 citations Open access
Semantic Scholar
OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
B. Cho, R. Obermannova, A. Bearz, Dohoung Kim +12 more
201716 citations Open access
Semantic Scholar
Analysis of Glucose Profiles in Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia (CML) Patients (pts) Treated with Nilotinib: Lack of Correlation between Glucose Levels and Nilotinib Efficacy.
P. le Coutre, F. Giles, A. Hochhaus, G. Martinelli +5 more
200710 citations
Semantic Scholar
P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous
R. Dziadziuszko, Dong-Wan Kim, A. Bearz, S. Laurie +8 more
20177 citations Open access
Semantic Scholar
Metformin-based oral antidiabetic therapy proved effective in hyperglycaemia associated with pasireotide in patients with acromegaly
A. Colao, F. Gu, M. Gadelha, A. J. van der Lely +5 more
20157 citations Open access
Semantic Scholar
Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAFV600E mutation-positive metastatic non-small cell lung cancer
Yun Fan, Jian-Ying Zhou, Yuan-Yuan Zhao, Yan Yu +11 more
2024Translational Lung Cancer Research6 citations Open access
Semantic Scholar
Abstract CT037: Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial
D. Tan, E. Felip, G. Castro, B. Solomon +18 more
2022Cancer Research6 citations
Semantic Scholar
445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with crizotinib
Lei Zhang, Y.-K. Shi, D. S. Tan, B. Hu +12 more
20165 citations
Semantic Scholar
Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression
F. Viola, A. Katz, A. Arantes, A. Gaiger +3 more
20075 citations
Semantic Scholar
Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1stline therapy in patients (pts) with advanced or metastatic NSCLC
B. Johnson, T. Kim, T. J. N. Hiltermann, F. Barlesi +14 more
2020Tumor Biology4 citations
Semantic Scholar
CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
D. Tan, T. Kim, B. Solomon, W. Tan +10 more
2019Annals of Oncology4 citations Open access
Semantic Scholar
Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in ALK+ metastatic NSCLC (ASCEND-8).
B. Cho, R. Obermannova, S. Orlov, U. Batra +15 more
2018Annals of Oncology4 citations Open access
Semantic Scholar
Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers
R. Kornberger, Lillian S. L. Ting, A. Tripathi, H. Rodrigues +3 more
2014Journal of clinical pharmacology3 citations Open access
Semantic Scholar
Prolactinomas resistentes a agonistas dopaminérgicos: diagnóstico e manejo
N. Musolino, V. Passos
20053 citations Open access
Semantic Scholar
Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3).
E. Felip, M. Nishio, S. Orlov, K. Park +11 more
2018Annals of Oncology2 citations Open access
Semantic Scholar
Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors.
T. Gyökeres, S. Pulgar, Neha Singh, V. Passos +1 more
2012Journal of Clinical Oncology2 citations
Semantic Scholar
[Dopamine-agonist resistant prolactinomas: diagnosis and management].
N. Musolino, V. Passos
2005Arquivos brasileiros de endocrinologia e metabologia2 citations
Semantic Scholar
Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
V. Subbiah, R. Kreitman, Z. Wainberg, A. Gazzah +18 more
2023Cancer Research1 citations
Semantic Scholar
Abstract CT192: Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) alone or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N
J. Lee, P. Garrido, Edward S. Kim, Ç. Arslan +7 more
2020Tumor Biology1 citations
Semantic Scholar
Canopy-1: Phase 3 Study of Canakinumab/Placebo + Pembrolizumab + Platinum-chemotherapy in Untreated Stage III b-IV NSCLC pts
E. Felip, G. Castro, A. Greystoke, B. Solomon +7 more
2020Pneumologie1 citations
Semantic Scholar
Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) as monotherapy or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N.
T. Mok, P. Garrido López, Edward S. Kim, Ç. Arslan +7 more
20201 citations
Semantic Scholar
Abstract C100: Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1stline therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)
B. Johnson, T. Kim, T. J. N. Hiltermann, F. Barlesi +15 more
2019Tumor Immunology Targets1 citations Open access
Semantic Scholar
P2.01-17 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts
E. Felip, G. Castro, A. Greystoke, B. Solomon +5 more
2019Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2)
M. Pavel, N. Singh, V. Passos, K. Öberg
20111 citations
Semantic Scholar
Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Patients with Surgically Resected Non-Small Cell Lung Cancer: CANOPY-N Trial
J. M. Lee, T. Mok, P. Garrido, E. S. Kim +8 more
TP137. TP137 THORACIC ONCOLOGY: DIAGNOSIS AND TREATMENT: IP, SURGERY, AND RADIATION1 citations Open access
Semantic Scholar
MO01.23 Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Patients with Surgically Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-N Trial
Jivianne T. Lee, P. Garrido, Edward S. Kim, Ç. Arslan +8 more
20210 citations Open access
Semantic Scholar
Abstract CT237: Canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in patients with surgically resected non-small cell lung cancer: CANOPY-N trial
J. Lee, T. Mok, P. Garrido, Edward S. Kim +8 more
2021Clinical Trials0 citations
Semantic Scholar
P03.05 CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in Patients With Surgically Resectable Non-Small Cell Lung Cancer
Jivianne T. Lee, M. Tsuboi, P. Garrido, Edward S. Kim +6 more
20210 citations Open access
Semantic Scholar
PD01.05 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients
B. Johnson, G. Castro, A. Greystoke, B. Solomon +5 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
Journal Pre-proof Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALK i-Naïve Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Phase II Study of in i-Naïve Patients With ALK -Rearranged Non–Small-Cell
M. Nishio, E. Felip, S. Orlov, Keunchil Park +13 more
20190 citations
Semantic Scholar
PDB34 MONITORING OF TREATMENT COSTS AFTER REIMBURSEMENT DECISION: SOMATOSTATIN ANALOGUES FOR ACROMEGALY
J. Valentim, V. Passos, A. Calabró
20080 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. McKeage×8
Invite
M. McKeage — researcher profile on SciRah
E. Felip×8
Invite
E. Felip — researcher profile on SciRah
A. Greystoke×7
Invite
A. Greystoke — researcher profile on SciRah
C. Blin×7
Invite
C. Blin — researcher profile on SciRah

V. Rodrik-Outmezguine

×7

Invite

V. Rodrik-Outmezguine — researcher profile on SciRah

Invite

B. Cho — researcher profile on SciRah

Yvonne Y. Lau×6

Invite

Yvonne Y. Lau — researcher profile on SciRah

Invite

S. Deudon — researcher profile on SciRah

Invite

P. Garrido — researcher profile on SciRah

Invite

J. Pujol — researcher profile on SciRah

Edward S. Kim×6

Invite

Edward S. Kim — researcher profile on SciRah

Invite

T. Mok — researcher profile on SciRah